Industry heavyweight, dubbed the ‘Godfather of Canadian cannabis’, Chuck Rifici has joined the board of one of Europe’s newest medical cannabis players.
Founding partner of UK-based Integro Medical Clinics, Eurox Pharma, plans to begin commercial production of cannabis based products in early 2021.
Canadian entrepreneur Rifici, who currently serves as executive chairman of Feather Company and co-founder of Canopy Growth Corporation and the Auxly Cannabis Group, will bring several years of expertise to the advisory role, as the firm sets out to become a major player in the medical cannabis market over the next five years.
Chuck Rifici has joined the advisory board of Eurox Pharma
Founded in 2019, it will produce a range of cannabis-based pharmaceuticals and products in Bensheim, Germany.
Its 10,000 sq meters manufacturing plant was certified as a fully GMP facility in October 2020, with the potential to manufacture 50 tonnes of product at full capacity.
Rifici, who previously served on the board of directors at Aurora Cannabis Inc, The Supreme Cannabis Company, Origin House and Meta Growth Corp, joins Amy Peckham, CEO of Etain Health, USA, and Michael Reckeweg, Chairman of Dr. Reckeweg & Co, on the advisory board.
The organisation is backed by cutting-edge research and together with its partners has a global distribution network.
In addition to its’ German operations Eurox is a founding partner in the cannabis medicines based Integro Medical Clinics Limited in the UK with leading British pharmaceutical company IPS.
Eurox was founded by ex-Deutsche Bank senior executive, Neil Smith, Bernhard Babel, ex- Partner at McKinsey & Co and David Reckeweg-Lecompte, CEO of Dr Reckeweg & Co, a 75 year old pharmaceutical company producing plant-based medicines in Germany.
“We are absolutely delighted to welcome Chuck, an industry legend to our organisation,” said co-CEO Smith.
“The experience and advice he will be able to offer us as a new player in the European cannabis pharmaceutical market will be invaluable. It is our goal to see Eurox as a major independent player in this market within the next three to five years.
“The market has massive growth potential which we intend to embrace and exploit.”